Nadine Tung

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer?
    Nadine Tung
    Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215
    J Clin Oncol 31:1391-7. 2013
  2. pmc Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice
    Laura N Burga
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston MA 02215, USA
    Breast Cancer Res 13:R30. 2011
  3. pmc Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers
    Eitan Friedman
    The Suzanne Levy Gertner Oncogenetics Unit, The Chaim Sheba Medical Center, Tel Hashomer, Israel, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Breast Cancer Res 8:R15. 2006
  4. pmc Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers
    Susan L Neuhausen
    Department of Epidemiology, University of California Irvine, 224 Irvine Hall, Irvine, CA 92697, USA
    Breast Cancer Res 11:R76. 2009
  5. pmc Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features
    Nadine Tung
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Brookline Avenue, Boston, MA 02215, USA
    Breast Cancer Res 12:R12. 2010
  6. doi request reprint Management of women with BRCA mutations: a 41-year-old woman with a BRCA mutation and a recent history of breast cancer
    Nadine Tung
    Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA
    JAMA 305:2211-20. 2011
  7. pmc Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers
    Nadine Tung
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Breast Cancer Res 12:R95. 2010
  8. doi request reprint Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers
    Larissa J Lee
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 117:3093-100. 2011
  9. pmc Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival
    Joyce Liu
    Department of Medical Oncology, Dana Farber Partners CancerCare, Boston, MA, USA
    Cancer Genet 205:34-41. 2012
  10. pmc Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate
    Theresa A Proia
    Department of Anatomy and Cellular Biology, Sackler School of Biomedical Research, Tufts University School of Medicine, 136 Harrison Ave, Boston, MA 02111, USA
    Cell Stem Cell 8:149-63. 2011

Collaborators

Detail Information

Publications13

  1. doi request reprint What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer?
    Nadine Tung
    Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215
    J Clin Oncol 31:1391-7. 2013
    ..She exercises regularly and takes a calcium supplement with vitamin D. Bone density study performed 6 months earlier was normal other than mild osteopenia in the femoral neck (T score, -1.3). Radiation therapy is planned...
  2. pmc Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice
    Laura N Burga
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston MA 02215, USA
    Breast Cancer Res 13:R30. 2011
    ..Here we examine the role of EGFR in mammary epithelial cells (MECs) in the emergence of BRCA1-related tumors and as a potential target for the prevention of TNBC...
  3. pmc Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers
    Eitan Friedman
    The Suzanne Levy Gertner Oncogenetics Unit, The Chaim Sheba Medical Center, Tel Hashomer, Israel, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Breast Cancer Res 8:R15. 2006
    ....
  4. pmc Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers
    Susan L Neuhausen
    Department of Epidemiology, University of California Irvine, 224 Irvine Hall, Irvine, CA 92697, USA
    Breast Cancer Res 11:R76. 2009
    ..In this study, we investigate the association of variants in genes involved in IGF signaling and risk of breast cancer in women who carry deleterious BRCA1 and BRCA2 mutations...
  5. pmc Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features
    Nadine Tung
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Brookline Avenue, Boston, MA 02215, USA
    Breast Cancer Res 12:R12. 2010
    ..We undertook a study to assess the clinical factors that predict for an estrogen receptor positive (ER+) breast cancer in BRCA1 mutation carriers and to characterize the pathologic features of these tumors...
  6. doi request reprint Management of women with BRCA mutations: a 41-year-old woman with a BRCA mutation and a recent history of breast cancer
    Nadine Tung
    Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA
    JAMA 305:2211-20. 2011
    ..The technology of preimplantation genetic diagnosis and genetic testing in relatives of mutation carriers is discussed...
  7. pmc Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers
    Nadine Tung
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Breast Cancer Res 12:R95. 2010
    ....
  8. doi request reprint Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers
    Larissa J Lee
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 117:3093-100. 2011
    ..The clinical outcome of women with and without BRCA1 mutations who had TN breast cancer treated with conventional chemotherapy were compared...
  9. pmc Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival
    Joyce Liu
    Department of Medical Oncology, Dana Farber Partners CancerCare, Boston, MA, USA
    Cancer Genet 205:34-41. 2012
    ..This may reflect important differences between BRCA genotypes and should be validated in larger studies...
  10. pmc Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate
    Theresa A Proia
    Department of Anatomy and Cellular Biology, Sackler School of Biomedical Research, Tufts University School of Medicine, 136 Harrison Ave, Boston, MA 02111, USA
    Cell Stem Cell 8:149-63. 2011
    ..These findings demonstrate that the genetic background of patient populations, in addition to affecting incidence rates, significantly impacts progenitor cell fate commitment and, therefore, tumor phenotype...
  11. doi request reprint Young adult daughters of BRCA1/2 positive mothers: What do they know about hereditary cancer and how much do they worry?
    ANDREA F PATENAUDE
    Dana Farber Cancer Institute, Boston, MA, USA Harvard Medical School, Boston, MA, USA
    Psychooncology 22:2024-31. 2013
    ....
  12. doi request reprint Does neoadjuvant bevacizumab increase surgical complications in breast surgery?
    M Golshan
    Department of Surgery, Brigham and Women s Hospital, Boston, MA, USA
    Ann Surg Oncol 18:733-7. 2011
    ..There are limited data on the safety of bevacizumab (bev) in the neoadjuvant setting. We sought to explore the safety of neoadjuvant cisplatin/bev in a protocol for triple negative breast cancer (TNBC)...
  13. pmc Wild-type BRCA1, but not mutated BRCA1, regulates the expression of the nuclear form of beta-catenin
    Huchun Li
    Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine, 99 Brookline Avenue, RN 330C, Boston, MA 02115, USA
    Mol Cancer Res 8:407-20. 2010
    ..This study provides evidence of a novel interaction between BRCA1 and beta-catenin, and that loss of BRCA1 leads to impaired expression of the nuclear form of beta-catenin, which may contribute to the pathogenesis of breast cancer...